MedTrace Logo

Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain

NCT02427516 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1144

Last updated 2016-09-20

No results posted yet for this study

Summary

To estimate annualized total cost rates (i.e. direct medical costs from hospitalizations, consultations, medications, and tests) of adequately controlling a patient (i.e. INR between 2-3 and TTR≥ 60%) diagnosed with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE), and treated with vitamin K antagonists (VKA) in Spain.

Conditions

  • Anticoagulation

Sponsors & Collaborators

  • Badalona Serveis Assistencials

    collaborator OTHER

  • IMS Health

    collaborator OTHER

  • Bristol-Myers Squibb

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2015-05-31
Completion
2015-11-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02427516 on ClinicalTrials.gov